News Headlines

  1. Biotechs Move Forward Developing Latest Targeted Therapies For Acute Myeloid Leukemia
    12/5/2019

    So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena.

  2. Almac Scientists To Develop Novel Manufacturing Process For Essential Medicine
    12/4/2019

    Almac Group, the global contract pharmaceutical development and manufacturing organisation, has been awarded $1M by the Bill & Melinda Gates Foundation (BMGF) to develop novel biosynthetic routes with the aim of substantially lowering the cost of selected steroidal Active Pharmaceutical Ingredients (APIs) and enable their use in developing world aid programs.

  3. TrialScope Launches Clinical Trials Website For EMD Serono
    12/3/2019

    TrialScope has worked with EMD Serono, the North American branch of the healthcare business of Merck KGaA, and CISCRP to launch a new clinical trials website. The site is designed to inform the public and healthcare professionals about the clinical trial journey and EMD Serono clinical trials.

  4. PPD Expands Special Patient Capabilities In Early Development Research
    12/3/2019

    PPD, Inc. (PPD) has expanded its early development research services by adding significant neuroscience and ethno-bridging expertise, broadening its capabilities to provide increased access to patients and special populations at PPD-owned clinical research units (CRUs).

  5. Inventiva Receives A €3.5M Milestone Payment From AbbVie
    12/3/2019

    Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the receipt of a milestone payment of 3.5 million euros following  the inclusion of the first patient with psoriasis in the ongoing clinical study with ABBV-157, a RORy inverse agonist jointly discovered by AbbVie and Inventiva for the treatment of autoimmune diseases.

  6. Signant Health Joins the Association Of Clinical Research Organizations (ACRO) To Add A Technology Perspective To Conversations With Legislators And Industry Leaders About The Future Of Clinical Research
    11/21/2019

    Signant Health announced today that it has joined the non-profit Association of Clinical Research Organizations (ACRO). ACRO, a global coalition of research and technology companies, makes it their mission to advocate as the collective voice of the innovative clinical research industry to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective and safe conduct of clinical research.

  7. Merck And Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint In Phase 3 Study Of Patients With Worsening Chronic Heart Failuremerck And Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint In Phase 3 Study Of Patients With Worsening
    11/18/2019

    Merck known as MSD outside the United States and Canada, today announced that the Phase 3 VICTORIA study evaluating the efficacy and safety of vericiguat, a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure, has met the primary efficacy endpoint.

  8. Signant Health And Actigraph Simplify Clinical Trial Activity And Sleep Monitoring For Patients, Sites, And Sponsors With Their New Integration
    11/14/2019

    Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax, with ActiGraph’s CentrePoint system.

  9. Premier Research Renews Sponsorship For World Orphan Drug Congress Europe
    11/8/2019

    Premier Research is proud to once again be a sponsor of the World Orphan Drug Congress (WODC) Europe taking place November 12-14, 2019, in Barcelona, Spain. As part of our ongoing support for this innovative conference, Jonathan Kornstein, Executive Director, Program Strategy, Rare Disease & Pediatrics, will present a session entitled "A Partnership That Lasts: Key Considerations When Working With CROs on Rare Disease Studies."

  10. Signant Health Proud To Sponsor The Philadelphia Walk To End Alzheimer’s In Nationwide Effort To Build Awareness, Raise Funds And Advance Research Towards A Cure
    11/8/2019

    Signant Health, formerly CRF Health and Bracket, announced today that it is sponsoring the Philadelphia Walk to End Alzheimer’s. The walk, which takes place on November 10, 2019 at Citizens Bank Park, Philadelphia, PA, is an annual fundraising event held by the Alzheimer’s Association.